On Wednesday, December 7, Curemark, a drug research and development company announced that CM-AT, a drug that treats the symptoms of autism in children ages 3 to 8 years old, is now in its late stage clinical trials.
Curemark reported the drug was now in phase-3 trial and showing statistically significant effects on symptoms of autism compared with a placebo on core and non-core symptoms. Curemark said the analysis of the full trial data is ongoing and the results will be presented at an upcoming medical meeting.
“We are extremely pleased with the results of our trial,” Curemark CEO Joan Fallon said. “We wish to thank all the children and their parents who participated in the study and look forward to a full review of the data by the FDA.”
The Food and Drug Administration has granted the drug fast-track status, a standard procedure for investigational drugs to treat serious or life-threatening conditions that may concentrate on chronic medical needs that have gone untreated.